Related Experiment Videos
Identification of Inhibitors against Metastasis Protein "Survivin:" In silico Discovery Using Virtual Screening and
Swechha Mishra1, Sangeeta Singh1
1Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, Uttar Pradesh, India.
Background:
In experimental therapy of cancer, survivin is considered to be one of the well-established targets. Studies have found that it is overexpression in most of the human tumors, but it is rarely found in normal tissues. It is having varied structural and functional role. It controls cell division and cellular stress response and also regulates metastasis and migration of cancerous cells. It has also been recognized as a biomarker which makes it unconventional drug target. In spite of being one of the centrally active components in metastasis and invasion, their clinical use is minimal. To increase the therapeutic efficiency of cancer and its various stages, it is important to survey novel reagents targeting the pathways and mechanism involving survivin.
Objective:
The aim of this study was to identify novel survivin inhibitor candidates using in silico screening.
Materials And Methods:
In this course of work, virtual screening on a dataset of natural compounds retrieved from ZINC and other libraries were performed. Comparative analysis of the protein was done by studying the binding affinity of inhibitors that are already available. The best interacting complex was set for molecular dynamics simulation for 25 ns to validate the stability of system. These molecules were checked for their toxicity and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties using OSIRIS and pre-ADMET tools.
Results:
We discovered ten such candidates with better binding efficiency with survivin in comparison to marketed chemical against the same. Furthermore, these inhibitor candidates did not induce cell toxicity. Binding affinity of reference molecules was varied from -6.8 to -8.5 kcal/mol while that of top scoring compound ZINC00689728 is -9.3 kcal/mol binding energy. Good placement and strong bond formation of selected molecule was observed during course of work. It is also having permissible ADMET property.
Conclusion:
Considering all the parameters, the screened molecule can be considered as a potential lead compound for designing new drug against survivin. Further investigation and testing will be required to make it to the final stage.
Summary:
Survivin is one of the important protein of metastasis. Inhibiting survivin might led to the increased therapeutic efficiency of cancer. In this work we are screening library of natural compounds in view of finding some potent inhibitor against survivin. Abbreviations used: MD: Molecular dynamics, LogS: Aqueous solubility, Acceptor HB: Hydrogen bond acceptor, Donor HB: Donor hydrogen bond donor, ADMET: Absorption, distribution, metabolism, excretion, and toxicity, RCSB: Research Collaboratory for Structural Bioinformatics, OPLS: Optimized potentials for liquid simulations, RMSD: Root-mean-square deviation.
Insights
This study identified novel natural compounds as potential survivin inhibitors using in silico screening. These candidates show strong binding affinity and favorable ADMET properties, offering new avenues for cancer therapy development.
Area of Science:
- Biochemistry
- Computational Chemistry
- Pharmacology
Background:
- Survivin is a key target in cancer therapy due to its overexpression in tumors and role in metastasis.
- Targeting survivin is crucial for enhancing cancer treatment efficacy.
- Novel therapeutic strategies are needed to inhibit survivin's functions.
Purpose of the Study:
- To identify novel survivin inhibitor candidates through in silico screening.
- To evaluate the binding affinity and drug-likeness of natural compounds against survivin.
Main Methods:
- Virtual screening of natural compounds from ZINC and other libraries.
- Comparative analysis of binding affinity with existing inhibitors.
- Molecular dynamics simulations to assess system stability.
- Toxicity and ADMET property prediction using OSIRIS and pre-ADMET tools.
Main Results:
- Ten novel survivin inhibitor candidates were identified with superior binding efficiency compared to marketed drugs.
- The top-scoring compound, ZINC00689728, exhibited a binding energy of -9.3 kcal/mol.
- Selected candidates demonstrated no induced cell toxicity and possessed permissible ADMET properties.
Conclusions:
- The screened natural compounds represent potential lead compounds for developing new survivin-targeting drugs.
- Further preclinical and clinical investigations are warranted to validate their therapeutic potential.
- Inhibiting survivin holds promise for improving cancer treatment outcomes.